PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Cancer Cell

Volumn 28, Issue 1, 2015, Pages 70-81

  Zou, HelenY ^a   Friboulet, Luc ^b   Kodack, DavidP ^b   Engstrom, LarsD ^a   Li, Qiuhua ^a   West, Melissa ^a   Tang, RuthW ^a,d   Wang, Hui ^a   Tsaparikos, Konstantinos ^a   Wang, Jinwei ^a   Timofeevski, Sergei ^a   Katayama, Ryohei ^c   Dinh, DacM ^a   Lam, Hieu ^a   Lam, JustineL ^a   Yamazaki, Shinji ^a   Hu, Wenyue ^a   Patel, Bhushankumar ^b   Bezwada, Divya ^b   Frias, RosaL ^b   Lifshits, Eugene ^b   Mahmood, Sidra ^b   Gainor, JustinF ^b   Affolter, Timothy ^a   Lappin, PatrickB ^a   Gukasyan, Hovhannes ^a   Lee, Nathan ^a   Deng, Shibing ^a   Jain, RakeshK ^b   Johnson, TedW ^a   Shaw, AliceT ^b   Fantin, ValeriaR ^a   Smeal, Tod ^a   more..

^a PFIZER INC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c CANCER INSTITUTE   (Japan)

^d METHYLGENE INC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALECTINIB; ALK INHIBITOR; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; CERITINIB; CRIZOTINIB; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; PF 06463922; PROTEIN ALK; PROTEIN EML4; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; ROS1 INHIBITOR; S6 KINASE; UNCLASSIFIED DRUG; 7-AMINO-12-FLUORO-2,10,16-TRIMETHYL-15-OXO-10,15,16,17-TETRAHYDRO-2H-8,4-(METHENO)PYRAZOLO(4,3-H)(2,5,11)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; MACROCYCLIC LACTAM; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MOUSE; MUTATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; PROTEIN DOMAIN; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; NEOPLASMS; SECONDARY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; LACTAMS, MACROCYCLIC; MICE; MUTATION; NEOPLASMS; NIH 3T3 CELLS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937521317     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.05.010     Document Type: Article

References (48)

1. Bagrodia S., Smeal T., Abraham R.T. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies. Pigment Cell Melanoma Res. 2012, 25:819-831.
2. Camidge D.R. Taking aim at ALK across the blood-brain barrier. J.Thorac. Oncol. 2013, 8:389-390.
3. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., Riely G.J., Solomon B., Ou S.H., Kim D.W., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012, 13:1011-1019.
4. Chen J., Jiang C., Wang S. LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. J.Med. Chem. 2013, 56:5673-5674.
5. Choi Y.L., Soda M., Yamashita Y., Ueno T., Takashima J., Nakajima T., Yatabe Y., Takeuchi K., Hamada T., Haruta H., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N.Engl. J. Med. 2010, 363:1734-1739. ALK Lung Cancer Study Group.
6. Costa D.B., Kobayashi S., Pandya S.S., Yeo W.L., Shen Z., Tan W., Wilner K.D. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J.Clin. Oncol. 2011, 29:e443-e445.
7. Costa D.B., Shaw A.T., Ignatius Ou S.-H., Solomon B.J., Riely G.J., Ahn M.-J., Zhou C., Shreeve S.M., Wiltshire R., Selaru P., et al. MO07.02 Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small cell lung cancer and brain metastasis in PROFILE 1005 and PROFILE 1007. Int. J. Thorac. Oncol. 2013, 8(Suppl. 2):S494-S495.
8. Costa D.B., Shaw A.T., Ou S.H., Solomon B.J., Riely G.J., Ahn M.J., Zhou C., Shreeve S.M., Selaru P., Polli A., et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J.Clin. Oncol. 2015, Published online January 26, 2015. 10.1200/JCO.2014.59.0539.
9. Crystal A.S., Shaw A.T., Sequist L.V., Friboulet L., Niederst M.J., Lockerman E.L., Frias R.L., Gainor J.F., Amzallag A., Greninger P., et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 2014, 346:1480-1486.
10. Cui J.J., Tran-Dubé M., Shen H., Nambu M., Kung P.P., Pairish M., Jia L., Meng J., Funk L., Botrous I., et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J.Med. Chem. 2011, 54:6342-6363.
11. Doebele R.C., Pilling A.B., Aisner D.L., Kutateladze T.G., Le A.T., Weickhardt A.J., Kondo K.L., Linderman D.J., Heasley L.E., Franklin W.A., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 2012, 18:1472-1482.
12. Friboulet L., Li N., Katayama R., Lee C.C., Gainor J.F., Crystal A.S., Michellys P.Y., Awad M.M., Yanagitani N., Kim S., et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014, 4:662-673.
13. Gadgeel S.M., Gandhi L., Riely G.J., Chiappori A.A., West H.L., Azada M.C., Morcos P.N., Lee R.M., Garcia L., Yu L., et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014, 15:1119-1128.
14. Gainor J.F., Shaw A.T. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J.Clin. Oncol. 2013, 31:3987-3996.
15. Gandhi L., Drappatz J., Ramaiya N.H., Otterson G.A. High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer. J.Thorac. Oncol. 2013, 8:e3-e5.
16. Gerber D.E., Minna J.D. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 2010, 18:548-551.
17. Huang Q., Johnson T.W., Bailey S., Brooun A., Bunker K.D., Burke B.J., Collins M.R., Cook A.S., Cui J.J., Dack K.N., et al. Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J.Med. Chem. 2014, 57:1170-1187.
18. Ignatius Ou S.H., Azada M., Hsiang D.J., Herman J.M., Kain T.S., Siwak-Tapp C., Casey C., He J., Ali S.M., Klempner S.J., Miller V.A. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J.Thorac. Oncol. 2014, 9:549-553.
19. Johnson T.W., Richardson P.F., Bailey S., Brooun A., Burke B.J., Collins M.R., Cui J.J., Deal J.G., Deng Y.L., Dinh D., et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J.Med. Chem. 2014, 57:4720-4744.
20. Kaneda H., Okamoto I., Nakagawa K. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer. J.Thorac. Oncol. 2013, 8:e32-e33.
21. Katayama R., Khan T.M., Benes C., Lifshits E., Ebi H., Rivera V.M., Shakespeare W.C., Iafrate A.J., Engelman J.A., Shaw A.T. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl. Acad. Sci. USA 2011, 108:7535-7540.
22. Katayama R., Shaw A.T., Khan T.M., Mino-Kenudson M., Solomon B.J., Halmos B., Jessop N.A., Wain J.C., Yeo A.T., Benes C., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 2012, 4:120ra17.
23. Katayama R., Friboulet L., Koike S., Lockerman E.L., Khan T.M., Gainor J.F., Iafrate A.J., Takeuchi K., Taiji M., Okuno Y., et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin. Cancer Res. 2014, 20:5686-5696.
24. Kim S., Kim T.M., Kim D.W., Go H., Keam B., Lee S.H., Ku J.L., Chung D.H., Heo D.S. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J.Thorac. Oncol. 2013, 8:415-422.
25. Kinoshita K., Asoh K., Furuichi N., Ito T., Kawada H., Hara S., Ohwada J., Miyagi T., Kobayashi T., Takanashi K., et al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg. Med. Chem. 2012, 20:1271-1280.
26. Kinoshita Y., Koga Y., Sakamoto A., Hidaka K. Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer. BMJ Case Rep. 2013, 2013.
27. Kodack D.P., Chung E., Yamashita H., Incio J., Duyverman A.M., Song Y., Farrar C.T., Huang Y., Ager E., Kamoun W., et al. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc. Natl. Acad. Sci. USA 2012, 109:E3119-E3127.
28. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., Ou S.H., Dezube B.J., Jänne P.A., Costa D.B., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N.Engl. J. Med. 2010, 363:1693-1703.
29. Lackner M.R., Wilson T.R., Settleman J. Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol. 2012, 8:999-1014.
30. Lovly C.M., McDonald N.T., Chen H., Ortiz-Cuaran S., Heukamp L.C., Yan Y., Florin A., Ozretić L., Lim D., Wang L., et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat. Med. 2014, 20:1027-1034.
31. Mager D.E., Wyska E., Jusko W.J. Diversity of mechanism-based pharmacodynamic models. Drug Metab. Dispos. 2003, 31:510-518.
32. Maillet D., Martel-Lafay I., Arpin D., Pérol M. Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. J.Thorac. Oncol. 2013, 8:e30-e31.
33. Rosenzweig S.A. Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem. Pharmacol. 2012, 83:1041-1048.
34. Sasaki T., Koivunen J., Ogino A., Yanagita M., Nikiforow S., Zheng W., Lathan C., Marcoux J.P., Du J., Okuda K., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011, 71:6051-6060.
35. Shaw A.T., Engelman J.A. ALK in lung cancer: past, present, and future. J.Clin. Oncol. 2013, 31:1105-1111.
36. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.J., De Pas T., Besse B., Solomon B.J., Blackhall F., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N.Engl. J. Med. 2013, 368:2385-2394.
37. Shaw A.T., Kim D.W., Mehra R., Tan D.S., Felip E., Chow L.Q., Camidge D.R., Vansteenkiste J., Sharma S., De Pas T., et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N.Engl. J. Med. 2014, 370:1189-1197.
38. Shaw A.T., Mehra R., Tan D., Felip E., Chow L., Camidge D.R., Vansteenkiste J., Sharma S., De Pas T., Riely G., et al. 1293P-Evaluation of ceritinib-treated patients (pts) with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastasis. Ann. Oncol. 2014, 25(Suppl_4):iv426-iv470.
39. Solomon B., Felip E., Blackhall F., Mok T., Kim D., Wu Y., Nakagawa K., Mekhail T., Paolini J., Usari T., et al. Overall and incranial (IC) efficacy results and time to symptom deterioration in PROFILE 1014: 1st line crizotinib vs. premetrexed-platinum chemotherapy (PPC) in pateints with advanced ALK-positive non-squamous non-smeall cell lung cancer (NSCLC). Ann. Oncol. 2014, 25(Suppl_4):iv426-iv470.
40. Solomon B., Wilner K.D., Shaw A.T. Current status of targetedtherapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clin. Pharmacol. Ther. 2014, 95:15-23.
41. Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., Felip E., Cappuzzo F., Paolini J., Usari T., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N.Engl. J. Med. 2014, 371:2167-2177. PROFILE 1014 Investigators.
42. Taipale M., Krykbaeva I., Whitesell L., Santagata S., Zhang J., Liu Q., Gray N.S., Lindquist S. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat. Biotechnol. 2013, 31:630-637.
43. Takeda M., Okamoto I., Nakagawa K. Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J.Thorac. Oncol. 2013, 8:654-657.
44. Tanizaki J., Okamoto I., Okabe T., Sakai K., Tanaka K., Hayashi H., Kaneda H., Takezawa K., Kuwata K., Yamaguchi H., et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin. Cancer Res. 2012, 18:6219-6226.
45. Weickhardt A.J., Scheier B., Burke J.M., Gan G., Lu X., Bunn P.A., Aisner D.L., Gaspar L.E., Kavanagh B.D., Doebele R.C., Camidge D.R. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J.Thorac. Oncol. 2012, 7:1807-1814.
46. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297:63-64.
47. Yamazaki S., Lam J.L., Zou H.Y., Wang H., Smeal T., Vicini P. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1. J.Pharmacol. Exp. Ther. 2014, 351:67-76.
48. Zou H.Y., Li Q., Engstrom L.D., West M., Appleman V., Wong K.A., McTigue M., Deng Y.L., Liu W., Brooun A., et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc. Natl. Acad. Sci. USA 2015, 112:3493-3498.